Journal
PHARMACOLOGICAL RESEARCH
Volume 163, Issue -, Pages -Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2020.105363
Keywords
Adenosinergic system; Adenosine; Major Depressive Disorder; Anxiety; Antidepressants
Categories
Funding
- Fundacao para a Ciencia e para a Tecnologia (FCT) [PTDC/BTM-SAL/32147/2017, PTDC/MED-FAR/30933/2017]
- H2020-WIDESPREAD-05-2017 -Twinning (EpiEpinet) [952455]
- FCT [SFRH/BD/147505/2019, PD/B D/150342/2019, PD/BD/113463/2015]
- Fundação para a Ciência e a Tecnologia [PD/BD/113463/2015, SFRH/BD/147505/2019, PTDC/BTM-SAL/32147/2017, PTDC/MED-FAR/30933/2017] Funding Source: FCT
Ask authors/readers for more resources
The review highlights the potential role of the adenosinergic system in the pathophysiology and treatment of MDD, with evidence suggesting alterations in this system in both MDD patients and animal models. Further research is needed to fully understand the impact of adenosine signaling in antidepressant treatments.
Major depressive disorder (MDD) is the foremost cause of global disability, being responsible for enormous personal, societal, and economical costs. Importantly, existing pharmacological treatments for MDD are partially or totally ineffective in a large segment of patients. As such, the search for novel antidepressant drug targets, anchored on a clear understanding of the etiological and pathophysiological mechanisms underpinning MDD, becomes of the utmost importance. The adenosinergic system, a highly conserved neuromodulatory system, appears as a promising novel target, given both its regulatory actions over many MDD-affected systems and processes. With this goal in mind, we herein review the evidence concerning the role of adenosine as a potential player in pathophysiology and treatment of MDD, combining data from both human and animal studies. Altogether, evidence supports the assertions that the adenosinergic system is altered in both MDD patients and animal models, and that drugs targeting this system have considerable potential as putative antidepressants. Furthermore, evidence also suggests that modifications in adenosine signaling may have a key role in the effects of several pharmacological and non-pharmacological antidepressant treatments with demonstrated efficacy, such as electroconvulsive shock, sleep deprivation, and deep brain stimulation. Lastly, it becomes clear from the available literature that there is yet much to study regarding the role of the adenosinergic system in the pathophysiology and treatment of MDD, and we suggest several avenues of research that are likely to prove fruitful.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available